Inhaled PEG IFNα-2b demonstrated a favorable safety and TK profile in juvenile rats at doses up to 1,202.4 ± 176.4 μg/kg, supporting its potential as an inhaled antiviral therapy for pediatric respiratory infections. This evidence concerns the gene IFNA2 and respiratory tract infectious disorder.